Detalhe da pesquisa
1.
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Cancer Immunol Immunother;
72(1): 91-99, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35729418
2.
Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab.
BMC Cancer;
23(1): 32, 2023 Jan 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36624467
3.
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Future Oncol;
17(23): 3007-3016, 2021 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34156285
4.
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol;
21(9): 1224-1233, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32888454
5.
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
BMC Cancer;
19(1): 1237, 2019 Dec 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31856742
6.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
N Engl J Med;
373(8): 726-36, 2015 Aug 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26287849
7.
Endoscopic resection of tracheal and bronchial granular cell tumours: A national multicentre retrospective study.
Respirology;
28(8): 794-797, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37301541
8.
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Lancet;
387(10026): 1405-1414, 2016 Apr 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26719230
9.
Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Br J Clin Pharmacol;
83(3): 623-631, 2017 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27662818
10.
Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.
Eur Arch Otorhinolaryngol;
274(7): 2883-2889, 2017 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28382396
11.
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Lancet Oncol;
17(2): 212-223, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26727163
12.
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
J Am Acad Dermatol;
74(6): 1077-85, 2016 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26946985
13.
Recurrent anaphylaxis to a gelatin-based colloid plasma substitute and to cetuximab following sensitisation to galactose-alpha-1,3-galactose.
Br J Anaesth;
126(6): e200-e202, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33810867
14.
How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.
Support Care Cancer;
24(3): 1131-8, 2016 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26268784
15.
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.
Eur Respir J;
46(5): 1440-50, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26381515
16.
Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test.
Future Oncol;
10(14): 2133-40, 2014 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25471028
17.
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.
Eur J Nucl Med Mol Imaging;
40(7): 985-96, 2013 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23564036
18.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol;
13(3): 239-46, 2012 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22285168
19.
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
J Clin Oncol;
41(15): 2682-2690, 2023 May 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37196429
20.
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Lung Cancer;
185: 107379, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37757576